Newsfeeds - Spark Newswire

3 minute read

Sorrento Therapeutics Completes Enrollment Of Phase 2 Clinical Trial Of Resiniferatoxin In Moderate To Severe Osteoarthritis Of The Knee Patients; Plans To Conduct An End Of Phase 2 Meeting With The FDA As Soon As Inital Top Line Data Is Available

Today, 5:11 AM

Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosed No limiting toxicities have been encountered during the trial to date. Patients are now being monitored for long-term safety and

SRNE

1 minute read

Sorrento Announces The Publication In The Nature Journal Scientific Reports The Details Of The Discovery Of SARS-CoV-2 Neutralizing Antibodies From The G-MAB Library

By Benzinga Newsdesk

Today, 5:11 AM

Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced publication of peer-reviewed data detailing the discovery and preclinical profiling of antibodies from the Sorrento

SRNE

1 minute read

FDA
News

Sorrento Reports Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept; Says Achieving Improvements In Rheumatoid Arthritis Disease Measures At 50% Of Standard Dose For Patients (7 of 7) With Inadequate Response To Subcuta

By Benzinga Newsdesk

Today, 5:11 AM

Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved significant improvements

SRNE

3 minute read

Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 5:11 AM

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck‘s (NYSE:MRK) lead asset MK-2060…

AMGN

1 minute read

Sorrento Shares Pop After Interim Data From Lung Cancer Trial

By Vandana Singh

Today, 5:11 AM

Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured long-term follow-up data.

AZN

2 minute read

Recap Of Friday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 5:11 AM

The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ:AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl)…

AXSM

1 minute read

Sorrento’s Scilex Holding Announces Expanding Coverage

By Benzinga Newsdesk

Today, 5:11 AM

30 million lives now covered by one of the largest national PBMs Continue to work with this PBM to access an additional 20 million lives The team continues to work with the national PBM's and health plans to

SRNE

4 minute read

Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary

By Ragothaman Srinivasan

Today, 5:11 AM

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

ALNA

1 minute read

Sorrento Shares Gain Following FDA’s Nod for Initial-Stage Covid-19 Study

By Ragothaman Srinivasan

Today, 5:11 AM

Sorrento Therapeutics (NASDAQ: SRNE) announced that the U.S. Food and Drug Administration (FDA) has cleared the Phase 1 study of its candidate, STI-1558, in patients with impaired renal and hepatic function.

SRNE

4 minute read

Sorrento’s Scilex Holding Company To Acquire Ancora Medical; Terms Not Disclosed

By Bill Haddad

Today, 5:11 AM

Ancora Medical Inc. ("Ancora") is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain management during

SRNE